trending Market Intelligence /marketintelligence/en/news-insights/trending/LGHvhJvkwtzG9T3XmynWTQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Gilead, Eisai to co-promote rheumatoid arthritis drug filgotinib in Japan

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Gilead, Eisai to co-promote rheumatoid arthritis drug filgotinib in Japan

Gilead Sciences Inc. and Tokyo-based Eisai Co. Ltd. entered an agreement to distribute and co-promote Gilead's rheumatoid arthritis treatment filgotinib in Japan.

Under the deal, Foster City, Calif.-based Gilead will be responsible for filgotinib's manufacturing and marketing approval while Eisai will oversee the medicine's distribution in Japan. The European Medicines Agency is currently reviewing Gilead's marketing application for filgotinib and the company has also filed an application with the Japanese Ministry of Health, Labor and Welfare for the medicine's approval.

Filgotinib, which inhibits an enzyme called Janus kinase 1, is not yet approved anywhere in the world. The medicine, which has been found to benefit patients in phase 3 trials, is also being evaluated as a treatment for ulcerative colitis, Crohn's disease and psoriatic arthritis.

Rheumatoid arthritis affects approximately 600,000 to one million people in Japan.

Gilead is developing filgotinib with Galapagos NV, and the companies have an agreement in place to commercialize filgotinib in inflammatory indications.